Adhesive Patch with Alkali Metal Fumarate for Cohesive Force
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional patches using rubber-based or silicone-based adhesive agents for emedastine exhibit insufficient cohesive force and deteriorated emedastine-release characteristics, leading to poor transdermal absorption and adhesive residue on the skin.
Innovation Solution
A patch design incorporating a combination of rubber-based and silicone-based adhesive agents with alkali metal fumarate, which acts as a cohesive force-improving agent, enhancing the adhesive layer's cohesiveness and emedastine-release characteristics, while maintaining effective transdermal absorption.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Strength
If a rubber-based adhesive agent is used in the adhesive agent layer, then the adhesive force to the skin is improved, but the cohesive force of the adhesive agent layer becomes insufficient and emedastine-release characteristics deteriorate
Solution Approach 1:
The patent combines a rubber-based adhesive agent with a specific rubber polymer (polyisoprene or polybutadiene) and emedastine to create a composite adhesive agent layer. This composite formulation resolves the contradiction by maintaining the adhesive properties of rubber-based adhesives while improving cohesive force and emedastine-release characteristics through the synergistic interaction of multiple components.
2Ease of manufacture
If emedastine and rubber-based adhesive agent are simply combined, then the patch can be manufactured easily, but the emedastine-release characteristics and transdermal absorption deteriorate
Solution Approach 1:
The patent specifies precise parameter ranges for the adhesive agent layer composition: emedastine at 0.1-10% by mass, rubber-based adhesive agent at 80-99.9% by mass, and specific ratios of polyisoprene to polybutadiene (0.1-5.0 by mass). These controlled parameter changes ensure reliable emedastine-release characteristics while maintaining ease of manufacture through a straightforward formulation approach.
3Ease of operation
If oral preparation of emedastine is used, then the drug can be administered conveniently, but the blood concentration fluctuates widely causing adverse effects
Solution Approach 1:
The patent replaces the oral administration route with transdermal delivery through a patch system. This substitution eliminates the gastrointestinal absorption variability that causes blood concentration fluctuations, providing stable drug delivery while maintaining convenience. The adhesive agent layer enables continuous transdermal absorption of emedastine at controlled rates.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The patch achieves improved cohesiveness and emedastine-release characteristics, reducing adhesive residue and enhancing transdermal absorption, thereby providing a more stable and effective delivery of emedastine.
Implementation Method 1
the alkali metal fumarate astonishingly acts as a cohesive force-improving agent for the adhesive agent layer
Implementation Method 2
the patch is also excellent in emedastine-release characteristics from the adhesive agent layer, and makes it possible to increase the transdermal absorption of emedastine
Data Source
Figure 1
Figure 2
AI summary
A patch comprising a support layer and an adhesive agent layer, wherein the adhesive agent layer comprises at least one drug selected from the group consisting of emedastine and pharmaceutically acceptable salts thereof , at least one adhesive agent selected from the group consisting of rubber-based adhesive agents and silicone-based adhesive agents, and an alkali metal fumarate as a cohesive force-improving agent for the adhesive agent layer.